ArticleBioinformatics (Oxford, England)2026
FFixR: a machine learning framework for accurate somatic mutation calling from FFPE RNA-seq data in cancer.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
motivationFormalin-fixed paraffin-embedded (FFPE) tissues are widely used in clinical and research settings, yet their use for detecting somatic mutations from RNA sequencing (RNA-seq) is hindered by artefactual mutations introduced by cytosine deamination and strand-specific damage. Existing FFPE noise-filtering tools are tailored to DNA sequencing (DNA-seq) and rely on strand bias, rendering them unsuitable for RNA-seq. Here, we present FFixR, a machine learning-based framework that filters FFPE-induced artefacts from RNA-seq data without requiring matched-normal samples.
resultsTrained on FFPE melanoma samples with matched DNA, FFixR leverages allele-specific read counts, variant features, and mutational signature probabilities. FFixR removed up to 98% of artefactual mutations while maintaining ∼92% recall of true variants. SHAP analysis revealed key feature interactions guiding model decisions. When applied to independent cohorts, FFixR restored the correlation between RNA- and DNA-derived tumor mutational burden (R2 = 0.881) and recovered biologically meaningful mutational signatures. FFixR enables accurate somatic variant calling from FFPE RNA-seq data, expanding the utility of archival samples for research and clinical applications. AVAILABILITY AND IMPLEMENTATION: FFixR tool is freely available on the web at https://github.com/yizhak-lab-ccg/FFixR and https://doi.org/10.6084/m9.figshare.31998315. The repository also includes a readme file describing the inputs, outputs and the entire pipeline. The results presented here were produced using v1.0.0.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.